GemciTest®, an in-vitro diagnostic that predicts the patient’s response to one of the therapies used to treat pancreatic cancer, benefits now from CE marking, which means it complies with current European regulations in force. Acobiom develops innovative blood diagnostics in the field of precision medicine. These tests, based on liquid biopsies (blood), aim to give…
Read more
On next November 21, 2019, the World Pancreatic Cancer Day 2019 will be organized. Key information about pancreatic cancer Pancreatic cancer is one of the world’s deadliest cancers. This cancer develops when cells of the organs grow out of control, developing a tumor. The pancreas is a gland located deep in the abdomen, between the…
Read more
Generating sequencing data from patient blood samples became easy to perform in clinical trials. But, analyzing the huge amount of genomic or transcriptomic data and extracting the key biomarkers associated with a clinical response to a specific therapy needs a tremendous combination of a scientific expertise, a biomolecular know-how, and a panel of bioinformatics and…
Read more
The Cancer Center (CGFL) of Dijon (France) launches a clinical study in 2018 to evaluate the prognostic value of on the overall survival and response to major treatments in patients diagnosed with pancreatic cancer. The CGFL is the sponsor of this study and the principal investigator is Professor François Ghiringhelli. In 2017, 14.000 new cases…
Read more
Acobiom became partner of the R-Link European program, which brings together 15 partners from 9 countries to develop a personalized approach to the medical care of patients suffering from bipolar disorders. This new approach is based on the discovery of biomarkers that predict lithium response. Acobiom, a company specializing in the discovery of biomarkers and…
Read more
Pancreatic cancer: the right treatment for the right patient Acobiom developed a diagnostic test to better target the treatment of pancreatic cancer patients. An innovation that should be on the market in 2019. 5%. The five-year survival rate of pancreatic cancer is extremely low. The Acobiom startup, located at the Euromedicine Biopole in Montpellier, wanted…
Read more
Metropolitain – 5/11/2017 START-UP: Biotech from Montpellier specialized in the discovery of new biological markers, Acobiom forecasts the launch of a test improving pancreatic cancer treatment Acobiom – 8 people including 6 researchers – works on the biomarker discovery and their association with drugs to improve the diagnostic and the efficiency of cancer treatment. Biotech…
Read more
Biotech Finances Article – 03/27/2017 Acobiom, company that identifies RNA biomarkers for the development of diagnostics in personalized medicine, seeks 2M€ funds by the end of 2017. This raising funds occurs in part of its involvement in Oncosnipe, a R&D collaborative program leaded by Oncodesign to develop diagnostic tools in personalized medicine, in breast, lung…
Read more
BioTech Finances – 10/12/2015 After 16 years of R&D, Acobiom is now able to predict that its companion diagnostic tests could be soon commercialized. Before that, the Montpellier-based company must complete a series of clinical trials evaluating the predictive efficacy of its tests in pancreatic cancer and Alzheimer’s disease. To finance this crucial step, the…
Read more
